Lung Transplant Week

HomePatientsLung Disease Week at the ATS2018 ▶ Lung Transplant Week
Lung Transplant Week

transplant

Welcome Message

Welcome to Lung Transplant Week at the ATS!

Lung transplantation is now considered a standard therapeutic intervention for several lung diseases that are advanced and refractory or progressive despite aggressive medical therapy. The number of lung transplants performed in the US and around the world continues to grow as the list of pulmonary diseases for which transplant is possible expands, and access to transplant centers and quality organs improves. The International Society for Heart and Lung Transplantation reports that through June 30, 2016, a total of 62,456 patients have received lung transplants. In 2015, over 4000 lung transplants were performed in 152 lung transplant centers worldwide.

Making the decision to undergo a lung transplant is not easy and requires the close coordination of care between the transplant center, patient, their physician and family. The entire process from initiating the referral to navigating a new medical system to the complexities of post-transplant care is daunting for all parties. Furthermore, lung transplant is not a cure. While short and medium-term outcomes are very good, with median 1-year survival of 86% and 3-year survival of 66%, long-term survival remains limited. Median survival rates differ depending on the disease being treated but overall, are around 6.1 years for patients who were transplanted between 1999-2008.  Fortunately, novel therapies are under investigation to treat chronic rejection, such as bronchiolitis obliterans, one of the primary causes of long-term mortality in lung transplant patients. 

ATS and partner organizations such as the Lung Transplant Foundation are dedicated to working together with clinicians, researchers, patients and their families to address the ongoing challenges in lung transplantation by continuing to increase awareness of and access to lung transplant as a therapeutic option and to improve the survival of and quality of life for lung transplant recipients.

 

awang

Angela Wang, MD
Scripps Clinic Medical Group
Member, ATS Board of Directors

Jeff Goldstein

Jeff Goldstein
President/Founder, Lung Transplant Foundation
Member, ATS Public Advisory Roundtable

 

ATS LUNG TRANSPLANT PARTNER

image

The Lung Transplant Foundation (LTF) was founded as a non-profit organization by a group of lung transplant recipients from Durham and Chapel Hill, NC. These recipients from Duke University and UNC Hospitals realized promotion and funding of research to improve the post lung transplant experience and long term outcomes was severely lacking, so they created the LTF to tackle one of the most difficult and life-threatening issues facing transplant recipients, chronic rejection or bronchiolitis obliterans syndrome (BOS).

 

Last Reviewed: September 2018